Published in AIDS Weekly, April 5th, 2010
These results indicate that using the SMARTube technology, developed by SMART Biotech, Ltd., physicians can create a "stimulation index," which can be used as a biomarker based on the ratio of stimulated (following pretreatment with SMARTube technology) to unstimulated antibodies, which can be measured by a conventional blood diagnostic assay. This index can be used to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.